Open AccessOutcomes of 50 Patients With Ewing Sarcoma Family of Tumors Treated at a Single Institution in Taiwan
Author(s) -
Chih-Ying Lee,
Chueh Chuan Yen,
Hsiu Ju Yen,
Cheng Ying Shiau,
TaChung Chao,
Po Kuei Wu,
Cheng-Fong Chen,
Paul Chih Hsueh Chen,
Hsiang Ling Wu,
Hong Jen Chiou,
ChaoChun Chen,
GiunYi Hung,
Wei Ming Chen
Publication year - 2016
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000003830
Subject(s) - medicine , sarcoma , oncology , distant metastasis , radiation therapy , demographics , metastasis , chemotherapy , ewing's sarcoma , cancer , pathology , demography , sociology
To identify the prognostic factors and long-term outcome of the Ewing sarcoma family of tumors (ESFT), data on 50 patients with ESFT treated at Taipei Veterans General Hospital between February 1991 and March 2014 were retrospectively considered. The influence of patient demographics, tumor features, and clinical and therapeutic parameters on overall survival (OS) and progression-free survival (PFS) rates were assessed. The results revealed that 21 of the 50 patients (42%) were metastatic at diagnosis. The median follow-up time was 1.8 years. The 5-year OS and PFS for patients who were nonmetastatic were 61.6% and 55.5%, respectively, and 18.8% and 15.4% for patients who were metastatic, respectively. The key adverse prognostic factor was metastasis at diagnosis. Radiotherapy for local control was associated with improved PFS. The high rate of primary metastasis and poorer outcomes of nonmetastatic ESFT compared with results from Western studies, along with previously reported low rates of ESFT in Taiwanese people, suggest that genetic factors play a role in the pathogenesis of ESFT and chemotherapy pharmacokinetics and pharmacodynamics. Radiotherapy in local treatment should be considered more aggressively in Taiwanese patients with ESFT.